所有图片(1)

主要文件

COO原产地证书/COA分析证书

查看所有文档

安全信息

安全和法规

M1750000

甲基强的松龙

Name: 甲基强的松龙
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

6α-甲基泼尼松龙, 11β,17α,21-三羟基-6α-甲基-1,4-孕甾二烯-3,20-二酮, 6α-甲基-11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮, 甲基强的松龙, 甲基泼尼松龙

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₂₂H₃₀O₅

CAS号:

83-43-2

分子量:

374.47

Beilstein:

2340300

MDL编号:

MFCD00010591

UNSPSC代码:

41116107

PubChem化学物质编号:

329817706

NACRES:

NA.24

推荐产品

Slide 1 of 10

1 of 10

USP

1435003

甲基强的松龙

Supelco

PHR1717

甲基强的松龙

BP248

甲基强的松龙

M1755200

Methylprednisolone hydrogen succinate

Y0001799

系统适用性试验A用甲泼尼龙

USP

1435014

Methylprednisolone Related Compound A

Y0001759

Methylprednisolone hydrogen succinate for peak identification

Sigma-Aldrich

C2874

CryoStor^® 细胞冻存培养基

USP

1437009

Methylprednisolone hemisuccinate

USP

1436006

醋酸甲泼尼龙

等级

pharmaceutical primary standard

API类

methylprednisolone

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

运输

wet ice

SMILES字符串

[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)CO

InChI

1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

InChI key

VHRSUDSXCMQTMA-PJHHCJLFSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? 访问产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Methylprednisolone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

警示用语：

Danger

危险声明

H360FD,H373

预防措施声明

P202 - P260 - P280 - P308 + P313 - P405 - P501

危险分类

Repr. 1B - STOT RE 2

靶器官

Adrenal gland,Immune system

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

法规信息

监管及禁止进口产品

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria.

Christiaan Fokke et al.

Brain : a journal of neurology, 137(Pt 1), 33-43 (2013-10-29)

Guillain-Barré syndrome is an acute polyradiculoneuropathy with a variable clinical presentation. Accurate diagnostic criteria are essential for patient care and research, including clinical trials and vaccine safety studies. Several diagnostic criteria for Guillain-Barré syndrome have been proposed, including the recent

Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome.

Juho Keski-Nisula et al.

The Annals of thoracic surgery, 95(6), 2126-2132 (2013-04-23)

Corticosteroids are widely used in pediatric open-heart surgery to reduce systemic inflammatory response and to mediate possible cardioprotective effects. However, the optimal dosing of corticosteroids is unknown and their administration varies considerably between different institutions. Forty neonates undergoing open-heart surgery

Spinal and paraspinal infections associated with contaminated methylprednisolone acetate injections - Michigan, 2012-2013.

MMWR. Morbidity and mortality weekly report, 62(19), 377-381 (2013-05-17)

As of May 6, 2013, Michigan had reported 167 (52%) of the 320 paraspinal or spinal infections without meningitis associated with the 2012-2013 fungal meningitis outbreak nationally. Although the index patient had a laboratory-confirmed Aspergillus fumigatus infection, the fungus most

Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease.

Tyree H Kiser et al.

American journal of respiratory and critical care medicine, 189(9), 1052-1064 (2014-03-13)

Studies evaluating corticosteroid (CS) dosing for patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) have largely excluded patients admitted directly to the intensive care unit (ICU), and none have evaluated the effect of CS dosing regimens

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Robert J Fox et al.

Neurology, 82(17), 1491-1498 (2014-04-01)

RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab. Eligible patients were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. Patients

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

主要文件

安全信息

甲基强的松龙

European Pharmacopoeia (EP) Reference Standard

About This Item

推荐产品

属性

等级

API类

制造商/商品名称

应用

包装形式

运输

SMILES字符串

InChI

InChI key

基因信息

说明

一般描述

应用

包装

其他说明

相关产品

相关产品

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

靶器官

储存分类代码

WGK

法规信息

文件

分析证书(COA)

已有该产品？

同行评审论文

技术服务